Samtidig indgift af IntronA med ribavirin øgede effekten af IntronA til mindst det dobbelte ved behandling af kronisk heptatitis C hos naive patienter.
Co-administration of IntronA with ribavirin increased the efficacy of IntronA by at least two fold for the treatment of chronic heptatitis C in naïve patients.